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SUMMARY
Acellular human dermal allografts have been shown to be effective for soft-tissue implantation. We compared treatment outcomes of 
tympanoplasty using tragal perichondrium and acellular human dermal allograft (MegaDerm®). In a prospective randomised controlled 
study, 60 patients scheduled to undergo tympanoplasty were randomly assigned to the autologous tragal perichondrium group (n = 33) or 
acellular human dermal allograft group (n = 27). Postoperative hearing gain, graft success rate at 1 and 6 months and operation times were 
compared between groups. Graft success rate, defined as the complete closure of tympanic membrane perforation, did not show any signifi-
cant intergroup difference (75.8% vs 85.2%, p = 0.519). Air conduction thresholds and air-bone gaps showed significant improvements in 
both groups; from 38.7 ± 15.9 dB to 30.2 ± 15.6 dB (p < 0.001) and from 17.8 ± 7.3 dB to 11.5 ± 7.0 (p = 0.001) in the autologous tragal 
perichondrium group, and from 30.4 ± 12.2 dB to 24.5 ± 13.0 dB (p = 0.006) and from 14.3 ± 5.1 dB to 7.6 ± 4.6 dB (p < 0.001) in the 
acellular human dermal allograft group. The amount of hearing gain (p = 0.31) and closure of air-bone gap (p = 0.863) were not meaning-
fully different between groups. The mean operation time was significantly lower in the acellular human dermal allograft group (35.2 min 
vs 27.4 min, p = 0.039). In this prospective randomised controlled study, acellular human dermal allograft was shown to be an effective 
alternative to tragal perichondrium, with similar graft success rates and postoperative hearing results, but with reduced operation times.
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RIASSUNTO 
Gli innesti eterologhi di materiale dermico acellulare hanno dimostrato la loro efficacia nei trapianti di tessuti molli. Nel presente studio sono 
stati paragonati i risultati derivati dall’utilizzo di pericondrio tragale e da innesto eterologo di materiale dermico acellulare (MegaDerm®) 
negli interventi di timpanoplastica. In modo prospettico randomizzato, 60 pazienti in nota per intervento di timpanoplastica sono stati assegnati 
casualmente ad un gruppo sottoposto ad intervento che prevedeva ricostruzione con cartilagine tragale (n = 33) o con innesto eterologo di 
materiale dermico acellulare (n = 27). Tra i due gruppi sono stati paragonati il guadagno uditivo postoperatorio, il tasso di successo della 
chirurgia ad 1 e 6 mesi e il tempo operatorio. Il tasso di successo della chirurgia, definito dalla completa chiusura della perforazione della 
membrana timpanica non ha mostrato alcuna differenza significativa tra i gruppi (75,8% vs 85,2%, p = 0,519). La soglia di conduzione per via 
aerea e il gap tra via aerea e via ossea hanno mostrato invece un significativo miglioramento in entrambi i gruppi considerati, da 38,7 ± 15,9 dB 
a 30,2 ± 15,6 dB (p < 0,001) e da 17,8 ± 7,3 dB a 11,5 ± 7,0 (p = 0,001) nel gruppo di pericondrio tragale autologo; da 30,4 ± 12,2 dB a 
24,5 ± 13,0 dB (p = 0,006) e da 14,3 ± 5,1 dB a 7,6 ± 4,6 dB (p < 0,001) nel gruppo di innesto eterologo di materiale dermico acellulare. La dif-
ferenza di guadagno uditivo (p = 0,31) e la chiusura del gap tra via aerea e via ossea (p = 0,863) non sono però risultati significativi tra i gruppi. 
Il tempo operatorio medio è risultato significativamente minore nel gruppo sottoposto ad innesto eterologo (35,2 min vs 27,4 min, p = 0,039). In 
questo studio prospettico randomizzato controllato, l’innesto eterologo di derma acellulare si è dimostrato come efficace alternativa all’utilizzo 
di pericondrio tragale, con tasso di successo chirurgico e risultati uditivi simili e minor tempo operatorio.
PAROLE CHIAVE: Timpanoplastica • Innesto eterologo • Matrice acellulare • Perforazione timpanica
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Introduction
Perforation of the tympanic membrane (TM) is a com-
mon disorder encountered by otologists. It is caused by 
trauma, chronic otitis media, or as a complication of oto-
logic surgeries, and presents with conductive hearing loss. 
The goals of tympanoplasty are to obtain an intact TM, 
eradicate pathological tissues in the middle ear and mas-
toid and reconstruct the sound transmission mechanism. 
Since first described by Berthold in 1878, various materi-
als have been used for TM grafting  1. Mostly, tissue lo-
cated near the operative field is harvested for grafting, and 
temporalis fascia and tragal perichondrium are the most 
commonly used grafting materials 2. These materials may 
be used solely or compositely such as perichondrium-car-
tilage island graft 3. In addition, various allografts, xeno-
grafts and alloplasts have been used in tympanoplasty 4. 
Among the various materials, human acellular dermal 
matrix has been used for TM grafting since late 20th 
century with promising results. However, there has been 
few prospective randomised trials to provide objective 
evidence justifying the use of this material. MegaDerm® 
(L&C BIO, Seongnam-si, Korea) is one such human acel-
lular dermal allograft derived from donated human skin 
that is supplied by US tissue banks under the guidelines of 
the American Association of Tissue Banks and US Food 
and Drug Administration. It consists of an intact basement 
membrane matrix processed directly from cadaveric skin, 
and allows for revascularisation by the recipient’s native 
fibroblasts and endothelial cells 5. Previous human acel-
lular dermal allografts (e.g., AlloDerm, LifeCell Corp., 
Branchbug, MJ, USA) are offered as an aseptic material; 
they are processed using methods to prevent, restrict, or 
minimise contamination with microorganisms. Mega-
Derm® is a sterile and non-immunogenic acellular der-
mal allograft. While processing the material, the cellular 
components of the epidermis and dermis are removed to 
allow the graft to be tolerated in the host without inciting 
an immune response 6. While sterility cannot be assured 
in an aseptic condition, MegaDerm® is produced using 
electron-beam sterilisation to eliminate viruses, bacteria 
and spores, achieving a 10-6 sterility level. Thus, theoreti-
cally, the use of a sterile allograft may also reduce the risk 
of infection. 
MegaDerm® has been shown to be effective in breast re-
construction 7, and numerous clinical applications includ-
ing rhinoplasty, penile augmentation, rotator cuff repair 
and preventing skin retraction after thyroidectomy and 
parotidectomy are under investigation. The use of Mega-
Derm® as a TM graft provides several benefits over na-
tive tissue. It can eliminate donor site morbidity, provide 
enough amount for grafting at any time and preserve na-
tive tissue for later use. In revision cases, in which the 
native tissue has already been consumed, it can be a good 
alternative available in infinite quantity. Moreover, since 
the procedures for harvesting and preparing graft tissue 
are unnecessary, operation times can also be reduced. 
Herein, we compared a group of similar, consecutive 
patients undergoing type  I tympanoplasty using Mega-
Derm® and native tissue (tragal perichondrium) in a 
prospective randomised controlled study. We compared 
outcomes of successful closure of TM perforation, au-
diologic outcomes and operation times for the different 
graft materials. 
Materials and methods
Patients
Sixty patients who underwent type I tympanoplasty for 
TM perforation between March 2015 and March 2016 
were included in the study. They were between 14 and 79 
years of age (mean age = 53.3 years); 17 (28.3%) were 
men and 43 (71.7%) were women. Patients who under-
went other procedures (e.g., ossiculoplasty or mastoidec-
tomy) simultaneously were excluded. None had a history 
of previous ear surgery, and their ear canal and middle ear 
were completely dried up without otorrhoea. Preoperative 
records showed that all of the perforations failed to close 
spontaneously over a 6-month period. They were random-
ly assigned to the native-tissue group (tympanoplasty us-
ing tragal perichondrium) or the MegaDerm® group (tym-
panoplasty using MegaDerm®). A third person assigned 
patients to each group by using a random number table, 
and informed the surgeon which materials were to be used 
on the same day of surgery. TM perforation was assessed 
using a 0°, 3 mm diameter straight telescope (Karl Storz 
GmbH & Co. KG, Tuttlingen, Germany) and a high-defi-
nition liquid crystal display monitor (Olympus, Tokyo, Ja-
pan). The perforations were grouped according to Saliba’s 
subdivision 8 as follows: small, less than 25% and less than 
1 quadrant size of the total TM; medium, more than 25% 
and less than 50%, and more than 1 quadrant and less than 
2 quadrant size; large, more than 50% but not total, and 
more than 2 quadrant size but not total; and total, 100% 
and 4 quadrant size. Patient information is listed in Table I. 
All procedures were in accordance with the Declaration 
of Helsinki of 1964. The study was approved by the Insti-
tutional Review Board of the Severance Hospital in Seoul, 
Korea (approval number: 4-2014-1072) and informed 
consent was obtained from all enrolled patients before 
surgery.
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Surgical procedure
All patients underwent type I tympanoplasty via the tran-
scanal approach under local anaesthesia. An ear speculum 
was inserted into the external auditory canal to visual-
ise the perforation. The margins of the perforation were 
trimmed by using a sharp pick. Then, the tympanomeatal 
flap was elevated, and the graft material was placed via 
an underlay technique. After grafting, the external audi-
tory canal was packed with antibiotic-coated gelfoam and 
sealed using an aseptic cotton ball and plaster. Patients 
were prescribed broad-spectrum oral antibiotics for 1 
week. All patients were discharged the same day.
In the native-tissue group, the tragal perichondrium was 
harvested as the graft. An additional skin incision was 
made over the tragus, and the perichondrium was har-
vested. Thereafter, the incision site was sutured with 4-0 
nylon. In the MegaDerm® group, a 1.5 × 2 cm graft (thick-
ness = 0.3-0.5 mm) was used. 
Assessment of treatment outcomes
Packing materials were completely removed at 2 weeks 
postoperatively, and the TM was assessed at 1 and 6 
months using the same device described above. Graft suc-
cess was defined as closure of the TM perforation. 
All patients underwent pure-tone audiography before, 
and at 1 and 6 months after surgery. Pure-tone air con-
duction (AC, 250-8,000  Hz) and bone conduction (BC, 
250-4,000  Hz) thresholds were measured using clinical 
audiometers in a double-walled audio booth. The average 
hearing threshold and air-bone gap (ABG) was defined as 
the mean value of the measurements taken at frequencies 
500 Hz, 1 kHz, 2 kHz, and 3 kHz. Postoperative hearing 
gain and closure of ABG were calculated by subtracting 
the mean preoperative AC thresholds from the mean post-
operative AC thresholds, and by subtracting the postop-
erative ABG from the preoperative ABG in both groups, 
respectively. Any complications that developed during the 
follow-up period were analysed. 
Operation time
Operation time, defined as the interval between the time 
of ear speculum insertion into the ear canal and time of 
postoperative dressing application, was analysed. 
Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics for Windows, Version 21.0 (IBM Corp., Armonk, 
NY, USA). The results of multiple experiments are pre-
sented as the mean ±standard deviation. Comparisons be-
tween continuous variables in two groups were performed 
using a Student’s t-test or the paired t-test for evaluating 
differences between two groups if the normality test was 
passed. Otherwise, the Mann-Whitney test or Wilcoxon 
signed rank test were applied. Comparisons between 
nominal variables in two groups were performed using 
Fisher’s exact test. A p value of 0.05 was considered as 
the threshold for significance.
Results
Among 60 patients, 27 (45.0 %) received MegaDerm®. 
Preoperative hearing level and ABGs for the two groups 
were not significantly different (p > 0.05, Table I). Age, 
perforation size and site of graft were not significantly 
different between the groups (p > 0.05, Table I), but the 
number of female patients was higher in the MegaDerm® 
group (p = 0.031, Table I).
Success in closing TM perforations
At 1 month postoperatively, 53 perforations were closed. 
However, six perforations in the native-tissue group 
(18.2%) and two in the MegaDerm® group (7.4%) re-
mained. The success rates for the two groups at 1 month 
were not significantly different (p = 0.276).
Among six perforations in the native-tissue group, two 
spontaneously closed at 6 months postoperatively. Three 
perforations remained at 6 months; but since their sizes 
were small and the patients were free from any ear symp-
toms; revision surgeries were not necessarily performed 
(Fig. 1A). One patient with remnant perforation needed 
revision surgery. It was a small-sized perforation located 
on the anteroinferior quadrant of the TM preoperatively 
Table I. Demographic and clinical characteristics of the study groups.
Variables Native Tissue 
Group  
(n = 33)
MegaDerm  
Group  
(n = 27)
P value
Age (yr) 53.7 ±15.2 52.8 ±13.5 0.808
Sex, n (%)
Male
Female
13 (39.4%)
20 (60.6%)
4 (14.8%)
23 (85.2%)
0.031
Site of graft, n (%)
Right
Left
16 (48.5%)
17 (51.5%)
9 (33.3%)
18 (66.7%)
0.244
Perforation Size, n (%)
Small
Medium
Large
Total
16 (48.5%)
16 (48.5%)
1 (3.0%)
0 (0)
13 (48.1%)
9 (33.3%)
4 (14.8%)
1 (3.8%)
0.295
Hearing level (dB HL)
Air conduction
Bone conduction
Air-bone gap
41.6 ±18.2
23.4 ±17.0
18.1 ± 6.8
36.4 ±17.1
20.9 ±14.9
15.5 ± 5.3
0.266
0.548
0.106
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(Fig.  2A), and a new perforation developed in the pos-
terior margin of the TM after tympanoplasty (Fig.  2B). 
Four perforations newly developed at 6 months postop-
eratively. Three of these were followed up without re-
vision surgery for the same reasons as above; however, 
one perforation needed revision surgery. It was initially a 
medium-sized perforation (Fig. 2C) and was completely 
closed at 1 month postoperatively. At 6 months, an oto-
scopic examination revealed a small-sized perforation 
with granulation tissue and otorrhoea growing in the mid-
dle ear space (Fig. 2D). Consequently, the graft success 
rate for the native-tissue group at 6 months was 75.8% 
(25/33), with two revision surgeries and six small pin-
point perforations. 
In the MegaDerm® group, two perforations were observed 
at 1 month postoperatively, and one needed revision sur-
gery. One was a large-sized perforation preoperatively 
(Fig. 2E), and had minimally decreased in size at 1 month 
postoperatively (Fig. 2F); therefore, revision surgery was 
performed. The other perforation was observed without 
additional treatment (Fig.  1B). Two perforations newly 
developed at 6 months postoperatively, and their sizes 
were so small that they were not treated. Therefore, the 
graft success rate for the MegaDerm® group at 6 months 
was 85.2% (23/27), with one revision surgery and three 
small pin-point perforations.
Consequently, 25 perforations from the native-tissue 
group and 23 perforations from the MegaDerm® group 
were successfully incorporated into the host TM without 
perforation (Fig. 3). The success rates for the two groups 
at 6 months were not significantly different (p = 0.519). 
We next determined if the graft success rate was dependent 
on the size and location of the perforation. Among the eight 
perforations in the native tissue group in which perforations 
failed to close, four were small-sized, and four were medi-
um-sized. Among the four perforations in the MegaDerm® 
group, two were small-sized, one was medium-sized and 
Fig. 1. Representative postoperative tympanic membrane (TM) findings. 
pin-point perforation developed at 1 month postoperatively and was ob-
served without treatment in the native-tissue group (A) and MegaDerm® 
group (B).
Fig. 2. Tympanic membrane (TM) photographs in patients who underwent 
revision surgeries. Two patients from the native-tissue group (A-D) and one 
from the MegaDerm® group (F and G) underwent revision surgeries (A, C and 
E represent preoperative TM findings; B and F represent TM findings at 1 
month postoperatively; D represents TM findings at 6 months postoperatively).
Fig. 3. Otoscopic views of the TM before and at 6 months postoperatively 
with complete TM closure. Approximately 75.8% of perforations in the na-
tive-tissue group (A, B), and 85.2% in the MegaDerm® group (C, D) showed 
successful closure, and the success rate was not significantly different be-
tween the two groups (p = 0.519).
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one was large-sized. In the native tissue group, two of the 
small-sized perforations were located anterosuperior and 
two were anteroinferior. In the native tissue group, one of 
the medium-sized perforations was located centrally, one 
was anterior and two were inferior. Two small-sized perfo-
rations of MegaDerm® group were located at anteroinferior 
quadrant of the drums, and a medium-sized perforation of 
MegaDerm® group was located at inferior region. Propor-
tion of size and location of the perforations did not signifi-
cantly differ between groups (Table II).
The size and location of the perforation and graft success 
rates were analysed. Perforations were initially classified 
into four groups, anterior small (n = 26), posterior small 
(n = 1), anterior medium (n = 11) and posterior medium 
(n = 1); the others, such as central or inferior perforations, 
were excluded due to the small number of cases. Of these, 
six anterior small-sized perforations and one anterior me-
dium-sized perforation failed to close. However, no statis-
tically significant differences were found between groups 
(p = 0.694) in the size of the perforations (p = 0.303) or 
the location of the perforations (p = 0.503). The overall 
graft success rate was also not significantly different be-
tween the two groups (p = 0.519). There was no difference 
in the successful closure of TM perforation based on size, 
location, or graft materials (Table II).
Hearing results 
At 1 month postoperatively, the AC threshold improved 
from 41.6  ±  18.2  dB to 35.2  ±  20.1  dB (p  <  0.001), 
and the BC threshold stabilised from 23.4 ± 17.0 dB to 
22.2  ±  17.6  dB (p  =  0.057) in the native-tissue group. 
Similar results were observed in the MegaDerm® group. 
The AC threshold improved from 36.4  ±  17.1  dB to 
31.3 ± 8.6 dB (p < 0.001), and the BC threshold stabi-
lised from 20.9 ± 14.9 dB to 19.7 ± 17.1 dB (p = 0.240). 
Hearing gain between the two groups was not signifi-
cantly different (p = 0.455, Fig. 4A, 4B). ABG was sig-
nificantly reduced in both groups, from 18.1  ±  6.8  dB 
to 13.1 ± 6.4 dB (p < 0.001) in the native-tissue group 
and from 15.5 ± 5.3 dB to 11.7 ± 5.7 dB (p = 0.002) in 
the MegaDerm® group. Therefore, ABG was reduced by 
5.1 ± 7.0 dB in the native-tissue group and by 3.8 ± 5.7 
dB in the MegaDerm® group, which was not significantly 
different (p = 0.455, Fig. 5A). 
Serial pure-tone audiograms were acquired in 34 pa-
tients (17 from each group) at 6 months postoperative-
ly. The other 26 patients referred no discomfort in sub-
jective hearing and refused to undergo hearing tests. 
The AC threshold improved from 38.7  ±  15.9  dB to 
30.2 ± 15.6 dB (p < 0.001) in the native-tissue group, and 
from 30.4  ±  12.2  dB to 24.5  ±  13.0  dB (p  =  0.006) in 
the MegaDerm® group. The BC threshold stabilised from 
20. 9 ± 15.4 dB to 18.8 ± 15.5 dB (p = 0.096) and from 
16.0 ± 10.0 dB to 16.8 ± 11.1 dB (p = 0.522) in the native-
tissue and MegaDerm® groups, respectively. Hearing gain 
was not different between the groups (p =0.31, Fig. 4C, 
4D). Both groups showed significantly reduced ABGs 
at 6 months postoperatively: 17.8 ± 7.3 dB to 11.5 ± 7.0 
(p = 0.001) in the native-tissue group and 14.3 ± 5.1 dB 
to 7.6  ±  4.6  dB (p  <  0.001) in the MegaDerm® group. 
The amount of reduction in ABGs was similar between 
the groups (p = 0.863, Fig. 5B).
Complications 
Except for the re-perforation or incomplete TM closure 
described above, few complications were observed. 
Table II. Perforation size and location.
Variables Native Tissue Group  
(n = 33)
MegaDerm Group  
(n = 27)
Small
• Anterosuperior
• Anteroinferior
• Posterosuperior
• Posterioinferior
• Central
16 (48.5%)
4
11
0
0
1
13 (48.1%)
0
11
0
1
1
Medium
• Anterior
• Posterior
• Inferior
• Central
16 (48.5%)
7
0
6
3
9 (33.3%)
4
1
4
0
Large 1 (3.0%) 4 (14.8%)
Total 0 (0) 1 (3.8%)
The proportion of perforation sites in the small-sized and medium-sized perforations did not differ significantly between groups (p = 0.215 and p = 0.528, respectively). Graft 
success rates did not differ based on perforation size (small vs medium, p = 0.303) or location (anterior vs posterior, p = 0.503). 
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Myringitis was reported in one patient in each group. They 
were treated with otic solution and oral medication, and 
the myringitis resolved without re-perforation. However, 
another patient from the native-tissue group had middle 
ear infection with re-perforation, requiring revision sur-
gery (Fig. 2B). One patient from the native-tissue group 
experienced donor-site perichondritis, which resolved 
without complications after oral medication. 
Operation time
The mean operation time was 35.2 ± 15.6 min in the na-
tive-tissue group and 27.4 ± 13.2 min in the MegaDerm® 
group. The operation times were significantly lower in the 
MegaDerm® group (p = 0.039). 
Discussion
There are several advantages to performing tympano-
plasty using a human acellular dermal allograft. First, the 
operation time can be significantly reduced. In our study, 
the use of MegaDerm® helped save on average 7.8 min 
over the use of tragal perichondrium. The longer opera-
tion time for autologous tissue grafting was because of 
the harvesting and handling of the graft material. Since 
Fig. 4. Preoperative and postoperative hearing results of the native-tissue group and MegaDerm® group measured at 1 (A, native-tissue group, n = 33; 
B, MegaDerm® group, n = 27) and 6 months (C, native-tissue group, n = 17; D, MegaDerm® group, n = 17) postoperatively. The air-conduction thresholds 
significantly improved in both groups, whereas the bone-conduction thresholds remained stable. The preoperative and postoperative air- and bone-conduction 
thresholds were not significantly different between the two groups (p = 0.266 and p = 0.445 for preoperative and postoperative air-conduction thresholds at 
1 month postoperatively; p = 0.548 and p = 0.584 for preoperative and postoperative bone-conduction thresholds at 1 month postoperatively; p = 0.096 and 
p = 0.252 for preoperative and postoperative air-conduction thresholds at 6 months postoperatively; p = 0.284 and p = 0.682 for preoperative and postop-
erative bone-conduction thresholds at 6 months postoperatively).
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MegaDerm® is prepared in a dried condition, surgeons do 
not need to wait for the material to dry as preferred, and 
can easily trim the material into the proper size and shape. 
MegaDerm® is as thick as 0.3-0.5 mm, which is generally 
thicker than native tissues, though still pliable, and the 
thickness and elasticity provide stability while handling 
the material. 
Second, an additional incision for harvesting the graft ma-
terial is unnecessary when using MegaDerm®, thus reduc-
ing donor-site morbidity. In cases in which tympanoplasty 
is performed via the transcanal approach, an additional 
incision is mandatory for harvesting the graft material 
unlike tympanoplasty via the retroauricular approach in 
which the temporalis fascia can be harvested via the same 
surgical site. This can reduce the probability of donor-site 
infection or deformity induced by injury to tragal carti-
lage. Reported donor-site infection is rare, but cannot be 
excluded 9. 
Third, the limitless supply of MegaDerm® is another ad-
vantage. In cases of revision surgery, finding enough suit-
able fascia or perichondrium is sometimes difficult, es-
pecially if the patient has undergone multiple surgeries. 
Finding autogenous tissues for grafting can be another 
time-consuming procedure and may increase donor-site 
morbidity. The authors also use MegaDerm® in canal-
wall-down mastoidectomy with tympanoplasty and re-
vision surgery, and the limitless supply of graft material 
could contribute to stable healing. 
MegaDerm® further offers an immunogenic benefit. The 
safety of acellular dermal matrix allografts has been well 
demonstrated in both animal  10 11 and clinical studies  12. 
Moreover, MegaDerm® is a sterile allograft produced by 
removing the antigenic target of cell-mediated rejection. 
A previous study comparing the rate of postoperative in-
fection between sterile allograft and aseptic allograft in 
breast reconstruction showed the superiority of the im-
munologic aspects of MegaDerm®  13. Although a direct 
comparison of these two materials in tympanoplasty has 
not yet been performed or reported, it can be stated that at 
least there is no harm in utilising MegaDerm® over native 
tissue or conventional allografts in view of its immuno-
genic superiority. 
In addition to the many advantages described above, 
MegaDerm® provides comparable functional benefits. 
Graft success rate varies according to materials and 
study designs. Success rates reported in retrospective 
studies were mostly higher than those reported in pro-
spective studies, regardless of the graft material used. 
In 2008, Gamra et al. reported a success rate of 97.7% 
for cartilage from 90  tympanoplasties, and a success 
rate of 96.9% for temporalis fascia from 290  tympa-
noplasties  14. Solmaz et al. performed 194  tympano-
plasties with perichondrium-cartilage island graft, and 
the success rate was 91.24% 3. A few other retrospec-
tive studies have reported similar outcomes. However, 
there are only two prospective studies reporting suc-
cess rates for cartilage and temporalis fascia. Yung et 
al. reported 84.2% and 80.0% success rates and Mauri 
Fig. 5. Changes in air-bone gaps (ABGs) after tympanoplasty (A, at 1 month postoperatively; B, at 6 months postoperatively). Significant reductions in ABGs 
were observed in both groups, and the amount of reduction of ABGs and postoperative ABGs were not significantly different between the two groups (p = 
0.455 at 1 month postoperatively; p = 0.863 at 6 months postoperatively).
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et al. reported 86.1% and 88.2% success rates for tem-
poralis fascia and cartilage 15 16. The reported success 
rates are quite comparable to those of MegaDerm® in 
this study. The success rate for allografts was simi-
lar to those for autologous materials. One study that 
performed tympanoplasty using allografts showed an 
88% success rate 17, and another reported a 78% suc-
cess rate for TM closure  18. With respect to hearing 
results, a prospective study with a large population of 
553 patients reported 12  month follow-up data; both 
AC and ABG improved from 32.1 dB to 29.7 dB and 
from 21.2 dB to 19.1 dB at 1 year postoperatively, re-
spectively, 19 and the improvement was comparable to 
that seen in our study. 
Since the first commercial use of allograft in tympano-
plasty in 1999, the advantages of this procedure have been 
widely reported 20. Numerous studies have provided evi-
dence for its safety and efficacy, including animal stud-
ies 21 22 and retrospective studies that compared and ana-
lysed methods and results  2  17  23. To our knowledge, the 
present study is the first and only prospective randomised 
controlled study in human patients demonstrating the ad-
vantages of the procedure. Therefore, the present study 
provides stronger support for the safety and efficacy of 
using allograft in tympanoplasty. 
Nevertheless, our study has some limitations. The func-
tion of the Eustachian tube highly affects the outcome 
of tympanoplasty in both disease recurrence and hearing 
improvement 24 25. Age, site of graft, perforation size and 
hearing level were matched in both groups, but the func-
tion of the Eustachian tube was neither assessed nor com-
pared. Although there is no available definite method that 
reflects the function of the Eustachian tube, information 
on preoperative Eustachian tube function could provide 
better comparison between groups and with previous re-
ports. Second, a 6 month follow-up period is likely to be 
sufficient to compare the efficacy of the materials; how-
ever, for better comparison, longer-term follow-up with 
more subjects is needed. 
Conclusions
Compared to autologous graft materials, MegaDerm® is 
an effective alternative as a TM graft material with similar 
graft success rates and postoperative hearing results, but 
with reduced operation times. 
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